News stories about IDEXX Laboratories (NASDAQ:IDXX) have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IDEXX Laboratories earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.974267853047 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

IDEXX Laboratories (NASDAQ IDXX) traded up $1.60 during midday trading on Friday, hitting $173.11. 632,940 shares of the company’s stock were exchanged, compared to its average volume of 477,798. The company has a market capitalization of $15,100.00, a PE ratio of 56.20, a PEG ratio of 2.29 and a beta of 0.42. IDEXX Laboratories has a 12-month low of $116.54 and a 12-month high of $173.82. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. The firm had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The company’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 earnings per share. analysts expect that IDEXX Laboratories will post 3.24 EPS for the current year.

IDXX has been the topic of a number of recent analyst reports. Canaccord Genuity reissued a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. BidaskClub cut shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective on the stock in a research note on Tuesday, October 24th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $173.67.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 54,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the sale, the chairman now owns 1,064,573 shares of the company’s stock, valued at $161,091,186.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $165.15, for a total transaction of $2,972,700.00. Following the sale, the chief executive officer now directly owns 1,077,112 shares in the company, valued at approximately $177,885,046.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 130,160 shares of company stock worth $20,019,685. Insiders own 2.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/01/12/idexx-laboratories-idxx-receiving-somewhat-positive-news-coverage-study-finds.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.